Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE Highlights
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
As a leading service provider in the field of antibody discovery and immunotherapy, Creative Biolabs now presents one-stop CAR-T therapy development service which has become a revolution in the area of cancer therapy. Now, We are proud to introduce mixed lymphocyte tumor reactivity assay (MLTR) as an efficient method to determine reactivity of engineered lymphocyte (CAR-T) and tumor cells to ensure CAR-T therapy.
Background
The mixed lymphocyte tumor reactivity assay (MLTR), also known as mixed lymphocyte tumor cell assay (MLTuC), is a technology to measure the immunological reactivity between lymphocyte and tumor cell. This assay was first described by in 1970 and was based on the mixed lymphocyte response (MLR) method which is used to show the safety of implantable material. Creative Biolabs provides CAR-T one-stop service from basic research to clinical trials and beyond, and MLTR assay has been a critical technology in evaluating the effectiveness of different CAR-T cell products at preclinical stage.
Assay of Mixed Lymphocyte Tumor Reactivity
Mixed lymphocyte tumor reactivity assay is based on mixed lymphocyte reaction assay, and now it has been an effective means to assess the immunological response between lymphocytes and tumor cells in vitro. It starts with co-culture target tumor cells (including cell line or tumor cells derived from patients) with lymphocyte populations (engineered with tumor-specific chimeric antigen receptor or primary T cells derived from PBMC), and then assess the immunological tumor-killing capabilities including T cell viability, activation, proliferation, and cytotoxicity by flow cytometry, ELISA, ELISpot etc. This assay also supports the measurement of interested antagonist or antibodies through the blockade of immune checkpoints as per clients' projects. Creative Biolabs offers this critical MLTR assay for our clients not only to validate the effectiveness of our CAR-T products, but also can help you to figure out a more promising approach to antitumor therapy.
Figure 1 Simple diagram of mixed lymphocyte tumor activity assay.
Highlight Features of Our Service
➢ Professional Ph.D. level scientists
➢ Skillful technologies and advanced platforms
➢ Time- and labor-saving
➢ Customized assay design
With years of extensive experience in the field of immunotherapy, Creative Biolabs has established advanced platforms to facilitate the projects of numerous worldwide customers. Our senior scientists promise timely troubleshooting to maximize the success of every project. We are dedicated to providing one-stop service to our clients from basic research to clinical trials. We offer the above assay but not limited to this. Please just let us know your requirement and our team will get back to you as soon as possible.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
